Session: TPS01 - Impact of HEMT on Health Outcomes Across the Spectrum of Disease
TPS01.5- Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation